QSAM Biosciences, Inc. is a clinical stage company developing next-generation nuclear medicines for the treatment of cancer. Our lead product, Samarium-153 DOTMP (CycloSam®), is an advanced therapeutic radiopharmaceutical for multiple indications: treatment of primary bone cancer and metastatic bone cancers from the breast, prostate and lungs; bone marrow ablation; and reduction in external radiation.
QSAM is not currently recruiting. To those receiving recruitment offers, this is unfortunately a scam and we advise you to cease any communications with any parties fraudulently representing QSAM.
Company Details
- Founded
- -
- Address
- 9442 N Capital Of Texas Hwy, Austin,texas 78759,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.qsambio.com
- HQ
- Austin, Texas
Qsam Biosciences, Inc. Questions
Qsam Biosciences, Inc.'s website is http://www.qsambio.com
Qsam Biosciences, Inc.'s LinkedIn profile is https://www.linkedin.com/company/qsam-biosciences-inc
Qsam Biosciences, Inc.'s industry is
Biotechnology Research
Qsam Biosciences, Inc.'s top competitors are
Isotherapeutics,
Alpha-9 Oncology,
Clarity Pharmaceuticals,
Monopar Therapeutics Inc.,
Actinium Pharmaceuticals, Inc.,
Telix Pharmaceuticals Limited,
Nordic Nanovector Asa,
Clovis Oncology,
Radiopharm Theranostics,
Plus Therapeutics, Inc..
Qsam Biosciences, Inc.'s categories are Biotechnology Research
Qsam Biosciences, Inc.'s founding year is 2020
